Study of the Effect of Vagus Nerve Stimulation on Human Brown Adipose Tissue Activity
Brown Adipose Tissue After Vagus Nerve Stimulation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Guy H. Vijgen, M.D.
- Phone Number: +31618942736
- Email: G.vijgen@maastrichtuniversity.nl
Study Contact Backup
- Name: Wouter D. van Marken Lichtenbelt, PhD.
- Phone Number: +31433881629
- Email: markenlichtenbelt@maastrichtuniversity.nl
Study Locations
-
-
-
Maastricht, Netherlands, 6200MD
- Recruiting
- Maastricht University
-
Contact:
- Guy H.E.J. Vijgen, M.D.
- Phone Number: 0433884252
- Email: g.vijgen@maastrichtuniversity.nl
-
Principal Investigator:
- Wouter D. van Marken Lichtenbelt, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects treated with VNS for epilepsy, aged 18-65 years, with a Body Mass Index (BMI) ≤ 28 kg/m2.
Exclusion Criteria:
- Body Mass Index > 28 kg/m2
- Daily epileptic insults.
- Subjects that need 'Rapid Cycling' VNS to control their frequency of epileptic insults.
- Psychological unstable subjects (as judged by the treating neurologist).
- subjects with mental retardation (as judged by the treating neurologist).
- subjects with severe behaviour disorders (as judged by the treating neurologist).
- Pregnant subjects.
- Subjects that previously underwent high dose radiation for diagnostic or therapeutic purposes (radiotherapy, high frequency CT-scans).
The use of the following medication is an exclusion criterium;
- ß-blockers,
- Ketogenic diet
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No treatment
|
No intervention
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
human brown adipose tissue activity
Time Frame: baseline and 2 weeks after
|
baseline and 2 weeks after
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Wouter D. van Marken Lichtenbelt, PhD., Department of Human Biology, Maastricht University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MEC 10-3-071
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.